Scopolamine butylbromide (Buscopan(r), BCP) has been used to as a spasmolytic for three decades. Although it is used to during routine ERCP, only few systemic studies have been carried out in patients to investigate its action on sphincter of
Oddi
(SO)
motility. To evaluate the effect of BCP on SO motility, We performed a biliary manometeric study in 15 patients (no pancreato-biliary disease: 5 cases, CBD stones: 7 cases, CBD cancer: 3 cases) undergoing routine diagnostic ERCP.
1) There was no significant difference of basal SO pressure, amplitude and frequency of phasic contraction between the patients with no pancreatobility disease, CBD stones, and CBD cancer.
2) In all of the 15 patients, the basal SO pressure, amplitude and frequency of phasic contraction were 14±6 mmHg, 127±25mmHg, and 4.1±0.9/min, respectively.
3) Administration of 10 mg BCP i. v. had abolished the phasic contractile activity of SO for average 6.23 minutes (range: 2.45~7.10 minutes).
4) After administration of BCP, the amplitude of phasic contraction of SO decreased from 127±25 mmHg to 78±34 mmHg, and the frequency of phasic contraction of SO from 4.1±0.9/min to 1.9±0.6/min. But the basal SO pressure was unaffected.
These results clearly demonstrate that BCP not only abolished the phasic contraction of SO, but also reduces the amplitude and frequency of phasic contraction of SO for a short period after i. v. administration.
|